EA201892137A1 - Композиции и способы получения антител, основанные на применении локусов, обеспечивающих повышенную экспрессию - Google Patents
Композиции и способы получения антител, основанные на применении локусов, обеспечивающих повышенную экспрессиюInfo
- Publication number
- EA201892137A1 EA201892137A1 EA201892137A EA201892137A EA201892137A1 EA 201892137 A1 EA201892137 A1 EA 201892137A1 EA 201892137 A EA201892137 A EA 201892137A EA 201892137 A EA201892137 A EA 201892137A EA 201892137 A1 EA201892137 A1 EA 201892137A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- methods
- compositions
- locuses
- application
- enhanced expression
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 241000699802 Cricetulus griseus Species 0.000 abstract 2
- 210000003527 eukaryotic cell Anatomy 0.000 abstract 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000010354 integration Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Analytical Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662325385P | 2016-04-20 | 2016-04-20 | |
| PCT/US2017/028552 WO2017184831A1 (en) | 2016-04-20 | 2017-04-20 | Compositions and methods for making antibodies based on use of an expression-enhancing locus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201892137A1 true EA201892137A1 (ru) | 2019-03-29 |
Family
ID=58701850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201892137A EA201892137A1 (ru) | 2016-04-20 | 2017-04-20 | Композиции и способы получения антител, основанные на применении локусов, обеспечивающих повышенную экспрессию |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US11530277B2 (enExample) |
| EP (1) | EP3445780A1 (enExample) |
| JP (2) | JP7134868B2 (enExample) |
| KR (2) | KR20180134894A (enExample) |
| CN (2) | CN109071633B (enExample) |
| AR (1) | AR108295A1 (enExample) |
| AU (2) | AU2017253240B2 (enExample) |
| BR (1) | BR112018071285A2 (enExample) |
| CA (1) | CA3015371A1 (enExample) |
| EA (1) | EA201892137A1 (enExample) |
| IL (2) | IL262268B2 (enExample) |
| MX (2) | MX2018012866A (enExample) |
| SG (2) | SG11201807881VA (enExample) |
| TW (1) | TW201803981A (enExample) |
| WO (1) | WO2017184831A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL275462B1 (en) * | 2017-12-22 | 2025-09-01 | Genentech Inc | Targeted integration of nucleic acids |
| WO2020034097A1 (en) * | 2018-08-14 | 2020-02-20 | Wuxi Biologics (Shanghai) Co., Ltd. | Transcriptional regulatory element and its use in enhancing the expression of exogenous protein |
| SG11202103334YA (en) * | 2018-10-26 | 2021-05-28 | Hoffmann La Roche | Multispecific antibody screening method using recombinase mediated cassette exchange |
| AU2019403279A1 (en) * | 2018-12-21 | 2021-07-01 | Genentech, Inc. | Targeted integration of nucleic acids |
| AU2020253023B2 (en) | 2019-03-29 | 2022-07-14 | F. Hoffmann-La Roche Ag | Method for the generation of an FcRn expressing cell by targeted integration of multiple expression cassettes in a defined organization |
| EP3950938A4 (en) | 2019-04-02 | 2023-01-18 | Chugai Seiyaku Kabushiki Kaisha | METHOD FOR INTRODUCING A FOREIGN TARGET-SPECIFIC GENE |
| CA3140323A1 (en) | 2019-06-19 | 2020-12-24 | Johannes Auer | Method for the generation of a multivalent, bispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization |
| CA3140297A1 (en) * | 2019-06-19 | 2020-12-24 | Simon Auslaender | Method for the generation of a protein expressing cell by targeted integration using cre mrna |
| KR20220024637A (ko) * | 2019-06-19 | 2022-03-03 | 에프. 호프만-라 로슈 아게 | 정의된 조직의 다수 발현 카세트들의 표적화 통합에 의한 3가 항체 발현 세포의 생성 방법 |
| CA3140318A1 (en) * | 2019-06-19 | 2020-12-24 | Johannes Auer | Method for the generation of a bivalent, bispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization |
| WO2020254351A1 (en) | 2019-06-19 | 2020-12-24 | F. Hoffmann-La Roche Ag | Method for the generation of a multivalent, multispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization |
| AU2020308002A1 (en) * | 2019-06-26 | 2022-01-20 | Genentech, Inc. | Randomized configuration targeted integration of nucleic acids |
| EP4087925A2 (en) * | 2020-01-10 | 2022-11-16 | F. Hoffmann-La Roche AG | Method for the assembly of large nucleic acids from short fragments |
| CN119731330A (zh) * | 2021-12-22 | 2025-03-28 | 基因泰克公司 | 多载体重组酶介导的盒式交换 |
| US20250122482A1 (en) | 2023-09-07 | 2025-04-17 | Regeneron Pharmaceuticals, Inc. | Production and purification of covalently surface modified adeno-associated virus |
| CN119955730A (zh) * | 2023-11-08 | 2025-05-09 | 深圳太力生物技术有限责任公司 | 一种细胞株及其制备方法与应用 |
| WO2025111473A1 (en) | 2023-11-21 | 2025-05-30 | Regeneron Pharmaceuticals, Inc. | Covalently surface modified adeno-associated virus production by in vitro conjugation, and purification of covalently surface modified adeno-associated virus |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4656134A (en) | 1982-01-11 | 1987-04-07 | Board Of Trustees Of Leland Stanford Jr. University | Gene amplification in eukaryotic cells |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| US6800457B2 (en) | 1998-09-22 | 2004-10-05 | Bristol-Myers Squibb Company | Expression vectors containing hot spot for increased recombinant protein expression in transfected cells |
| CA2485939C (en) | 2002-05-29 | 2013-10-29 | Regeneron Pharmaceuticals, Inc. | Inducible eukaryotic expression system |
| AU2003298674A1 (en) | 2002-11-14 | 2004-06-15 | Genentech Inc | Intron fusion construct and method of using for selecting high-expressing production cell lines |
| JP5620626B2 (ja) | 2005-03-31 | 2014-11-05 | 中外製薬株式会社 | 会合制御によるポリペプチド製造方法 |
| WO2007110205A2 (en) | 2006-03-24 | 2007-10-04 | Merck Patent Gmbh | Engineered heterodimeric protein domains |
| CA2652976C (en) | 2006-06-02 | 2015-08-11 | Regeneron Pharmaceuticals, Inc. | High affinity antibodies to human il-6 receptor |
| WO2008079943A2 (en) | 2006-12-21 | 2008-07-03 | Smithkline Beecham Corporation | Novel methods |
| US20080216185A1 (en) | 2007-01-19 | 2008-09-04 | Invitrogen Corporation | Compositions and Methods for Genetic Manipulation and Monitoring of Cell Lines |
| AU2008234248C1 (en) | 2007-03-29 | 2015-01-22 | Genmab A/S | Bispecific antibodies and methods for production thereof |
| WO2008151219A1 (en) | 2007-06-04 | 2008-12-11 | Regeneron Pharmaceuticals, Inc. | Enhanced expression and stability regions |
| PT2235064E (pt) | 2008-01-07 | 2016-03-01 | Amgen Inc | Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática |
| PL2438171T3 (pl) | 2009-06-02 | 2015-04-30 | Regeneron Pharma | Komórki z niedoborem fukozylacji |
| MX368932B (es) | 2009-06-26 | 2019-10-22 | Regeneron Pharma | Anticuerpos biespecificos facilmente aislados con formato de inmunoglobulina original. |
| CA2781519A1 (en) | 2009-09-16 | 2011-03-24 | Genentech, Inc. | Coiled coil and/or tether containing protein complexes and uses thereof |
| CN110066339A (zh) | 2010-04-20 | 2019-07-30 | 根马布股份公司 | 含异二聚体抗体fc的蛋白及其制备方法 |
| EP2606064B1 (en) | 2010-08-16 | 2015-02-25 | NovImmune S.A. | Methods for the generation of multispecific and multivalent antibodies |
| HUE068728T2 (hu) | 2011-08-05 | 2025-01-28 | Regeneron Pharma | Humanizált univerzális könnyûláncú egerek |
| TW201823460A (zh) | 2012-05-29 | 2018-07-01 | 美商再生元醫藥公司 | 生產細胞株增強子 |
| EP2711428A1 (en) | 2012-09-21 | 2014-03-26 | Lonza Biologics plc. | Site-specific integration |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| TWI675044B (zh) | 2012-11-14 | 2019-10-21 | 美商再生元醫藥公司 | 重組細胞表面捕捉蛋白質 |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| US20140308285A1 (en) | 2013-03-15 | 2014-10-16 | Amgen Inc. | Heterodimeric bispecific antibodies |
| TWI670283B (zh) | 2013-12-23 | 2019-09-01 | 美商建南德克公司 | 抗體及使用方法 |
| TWI701042B (zh) | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| KR102243243B1 (ko) * | 2014-10-23 | 2021-04-22 | 리제너론 파마슈티칼스 인코포레이티드 | 신규한 cho 통합 부위 및 이의 용도 |
| CN108290951B (zh) | 2015-09-23 | 2022-04-01 | 瑞泽恩制药公司 | 优化抗cd3双特异性抗体和其用途 |
-
2017
- 2017-04-20 EP EP17723182.6A patent/EP3445780A1/en active Pending
- 2017-04-20 TW TW106113300A patent/TW201803981A/zh unknown
- 2017-04-20 BR BR112018071285A patent/BR112018071285A2/pt not_active Application Discontinuation
- 2017-04-20 WO PCT/US2017/028552 patent/WO2017184831A1/en not_active Ceased
- 2017-04-20 CN CN201780024560.2A patent/CN109071633B/zh active Active
- 2017-04-20 AR ARP170101018A patent/AR108295A1/es unknown
- 2017-04-20 SG SG11201807881VA patent/SG11201807881VA/en unknown
- 2017-04-20 US US16/095,067 patent/US11530277B2/en active Active
- 2017-04-20 KR KR1020187029371A patent/KR20180134894A/ko not_active Ceased
- 2017-04-20 MX MX2018012866A patent/MX2018012866A/es unknown
- 2017-04-20 IL IL262268A patent/IL262268B2/en unknown
- 2017-04-20 EA EA201892137A patent/EA201892137A1/ru unknown
- 2017-04-20 KR KR1020217035334A patent/KR102474757B1/ko active Active
- 2017-04-20 SG SG10202010156XA patent/SG10202010156XA/en unknown
- 2017-04-20 JP JP2018552822A patent/JP7134868B2/ja active Active
- 2017-04-20 IL IL309065A patent/IL309065A/en unknown
- 2017-04-20 AU AU2017253240A patent/AU2017253240B2/en active Active
- 2017-04-20 CA CA3015371A patent/CA3015371A1/en active Pending
- 2017-04-20 CN CN202211344339.4A patent/CN116004544A/zh active Pending
-
2018
- 2018-10-19 MX MX2024014381A patent/MX2024014381A/es unknown
-
2022
- 2022-08-31 JP JP2022137796A patent/JP7546015B2/ja active Active
-
2024
- 2024-09-26 AU AU2024220126A patent/AU2024220126A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017184831A1 (en) | 2017-10-26 |
| AR108295A1 (es) | 2018-08-08 |
| JP2024164196A (ja) | 2024-11-26 |
| JP7546015B2 (ja) | 2024-09-05 |
| KR102474757B1 (ko) | 2022-12-07 |
| BR112018071285A2 (pt) | 2019-02-12 |
| CN116004544A (zh) | 2023-04-25 |
| CA3015371A1 (en) | 2017-10-26 |
| JP2022164824A (ja) | 2022-10-27 |
| AU2024220126A1 (en) | 2024-10-17 |
| AU2017253240B2 (en) | 2024-07-04 |
| SG10202010156XA (en) | 2020-11-27 |
| AU2017253240A1 (en) | 2018-09-20 |
| EP3445780A1 (en) | 2019-02-27 |
| US20190263937A1 (en) | 2019-08-29 |
| JP2019514358A (ja) | 2019-06-06 |
| MX2024014381A (es) | 2024-12-06 |
| JP7134868B2 (ja) | 2022-09-12 |
| KR20180134894A (ko) | 2018-12-19 |
| US20230322956A1 (en) | 2023-10-12 |
| SG11201807881VA (en) | 2018-10-30 |
| KR20210135340A (ko) | 2021-11-12 |
| US11530277B2 (en) | 2022-12-20 |
| TW201803981A (zh) | 2018-02-01 |
| IL309065A (en) | 2024-02-01 |
| CN109071633A (zh) | 2018-12-21 |
| CN109071633B (zh) | 2022-11-18 |
| IL262268A (en) | 2018-11-29 |
| MX2018012866A (es) | 2019-03-11 |
| IL262268B1 (en) | 2024-01-01 |
| IL262268B2 (en) | 2024-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201892137A1 (ru) | Композиции и способы получения антител, основанные на применении локусов, обеспечивающих повышенную экспрессию | |
| EA201892010A1 (ru) | Композиции и способы получения антител, основанные на применении локусов, обеспечивающих повышенную экспрессию | |
| EA202090931A3 (ru) | Композиции и способы перепрограммирования tcr с помощью гибридных белков | |
| ZA202308519B (en) | Anti-vegf protein compositions and methods for producing the same | |
| EA201992001A1 (ru) | Композиции и способы повышения экспрессии генов | |
| CA2971734C (en) | Anti-pd-1 antibodies | |
| EA202091672A1 (ru) | Стероиды и их антитело-конъюгаты | |
| EA201991168A1 (ru) | Белок, связывающий простатический специфический мембранный антиген | |
| BR112019007288A2 (pt) | proteína heterodimérica biespecífica, composições de ácido nucleico e de vetor de expressão, vetor de expressão, célula hospedeira, e, métodos para produzir proteína heterodimérica biespecífica e para tratar câncer em um paciente | |
| MX2018003353A (es) | Terapias con celulas cart con una eficacia mejorada. | |
| MX2023000738A (es) | Proteinas de union a antigeno que activan el receptor de leptina. | |
| TR201809571T4 (tr) | Ll-22 polipeptidleri ile ıl-22 fc füzyon proteinleri ve kullanım yöntemleri. | |
| MX2017000083A (es) | Compuestos de platino, composiciones y usos de estos. | |
| EA201791918A1 (ru) | Модификация белков клеток-хозяев | |
| EA201892588A1 (ru) | Прямой отбор клеток, экспрессирующих высокие уровни гетеромерных белков, с использованием глутаминсинтетазных векторов внутригенной комплементации | |
| EA201792466A1 (ru) | АНТИТЕЛА ПРОТИВ FcRn | |
| EA201990758A1 (ru) | Способ получения электрокомпетентных дрожжевых клеток и способ применения указанных клеток | |
| PH12021550096A1 (en) | Compositions of fcrn antibodies and methods of use thereof | |
| EA201691691A1 (ru) | Белки слияния tatk-cdkl5, их композиции, составы и применение | |
| EA201691548A1 (ru) | Экспрессирующие конструкции и способы для отбора клеток-хозяев, экспрессирующих полипептиды | |
| EA201790241A1 (ru) | Эффективная селективность в отношении рекомбинантных белков | |
| EA201900275A1 (ru) | Стероиды и их конъюгаты с белками | |
| AR103810A1 (es) | Modificación de proteína de célula hospedante | |
| EA201990543A1 (ru) | Композиции и способы репрограммирования т-клеточных рецепторов с помощью гибридных белков | |
| EA202090582A3 (ru) | Полипептиды il-22, химерные белки il-22 fc и их применение |